MedTrace Logo

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

NCT00697385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2008-09-19

No results posted yet for this study

Summary

The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments. This has led to development of this protocol in order to make available tranexamic acid as a potentially effective menorrhagia therapy option in women with an underlying bleeding disorder. We anticipate that Tranexamic Acid may be a beneficial choice for controlling menorrhagia in bleeding disorder patients.

Conditions

  • vonWillebrand Disease
  • Hemophilia
  • Platelet Coagulation Disorders

Interventions

DRUG

Cyclokapron

(2) 500mg tablets taken by mouth every 6-8 hours

Sponsors & Collaborators

  • Mary M. Gooley Hemophilia Center

    lead OTHER

Principal Investigators

  • Peter A Kouides, MD · Mary M. Gooley Hemophilia Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697385 on ClinicalTrials.gov